2026-11-05 · contested story
HHS clears six peptides for compounding, overriding FDA scientists' objections
In late July 2026, an FDA advisory panel (the Pharmacy Compounding Advisory Committee) narrowly recommended that compounding pharmacies be allowed to make six of seven popular but unproven peptides — including BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon — over the explicit objections of the FDA's own career scientists, who found insufficient human data and flagged safety concerns like immunogenicity and tumor growth. On October 28, 2026, HHS Secretary Robert F. Kennedy Jr.'s department issued an 'enforcement discretion' policy allowing those six peptides to be compounded while formal rulemaking proceeds — bypassing the FDA's normal process. The debate pits advocates who say a regulated compounding pathway would pull consumers out of a dangerous 'gray market' of overseas research-chemical sellers against safety experts who warn that legitimizing untested drugs threatens the FDA's decades-old drug-vetting system. The National Review framing article tying this to FDA-nominee Heidi Overton's 'go fast' deregulatory posture was paywalled in our scrape, so the explicit 'peptides speed biologic competition' thesis is thin in the gathered text.
How each side frames it
left
"Overruling his own Food and Drug Administration—because fuck those pencilnecks, am I right?—Kennedy announced Wednesday that basically everyone can get unapproved peptide injections."
"no one has looked into whether it will give you cancer or even kill you"
"Please don't inject yourself with bootleg peptides"
"The peptide business has caught the attention of major telehealth providers, including Hims & Hers... Wall Street analysts estimate the market could be worth more than $2 billion."
"As people 'are diverted from those drugs toward this stuff, there will be more unnecessary pain and suffering,' said Lurie"
center
"Supporters of a regulated pathway argue that it could draw consumers away from an unregulated market... At the same time, critics warn that consumer enthusiasm should not substitute for rigorous evidence."
"The FDA's peptide vote could create telehealth's next multibillion-dollar market"
"Is the FDA going to stand on science or is it going to permit all kinds of snake oil to be readily available?"
"even if regulators decline to expand access, industry participants say consumer demand is likely to remain strong"
"The upcoming meeting represents yet another tension point between Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda and the traditional medical and scientific establishment."
right
"Slow and prohibitive requirements for cutting edge therapies at the FDA means investment is increasingly flowing to China."
"my growing sympathy for libertarian critiques of the FDA"
"We need to embrace a learn-as-we-go strategy that doesn't simply ask one narrow question at a time, in one trial at a time. The current drug development and approval system is too expensive, too time consuming, and, frankly, unethical."
"This is not a rubber stamp... This is about moving towards a regulated pathway for peptides that patients are already using."
What each side left out
The right left out — covered by the NPR & NBC News & The Washington Post & Bloomberg Law
- Substantive reporting on the peptide safety/efficacy debate itself
- FDA scientists' specific objections (immunogenicity, no human data, tumor growth)
- Conflict-of-interest concerns about the reconstituted advisory panel
The left left out — covered by the Bloomberg Law & KELO-AM (Reuters) & Hims & Hers Newsroom
- The economic/competition argument that faster approvals lower drug prices
- The gray-market safety rationale taken on its own merits
- Compounding pharmacies' quality-standard and adverse-event-reporting safeguards
The center left out — covered by the The Boston Globe & Daily Kos
- Strong normative judgment about whether bypassing the FDA is dangerous
- The MAHA-electoral-timing critique
The right left out — covered by the NBC News & The Guardian
- Industry conflict-of-interest in panel appointments (e.g., Bobby Harshbarger)
- That FDA career staff opposed the policy
What's actually true?
[verified] An FDA advisory panel in late July 2026 voted to recommend adding six of seven peptides to the compounding list, rejecting only emideltide.
[verified] FDA career scientists recommended against adding any of the seven peptides to the compounding list, citing insufficient human data and safety concerns.
[verified] On October 28, 2026, HHS issued an 'enforcement discretion' policy covering six peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c, Semax), bypassing the FDA's formal rulemaking.
[verified] FDA scientific staff largely opposed the HHS policy and had limited input in drafting it, per six people familiar with its development.
[verified] RFK Jr. has called himself a 'big fan' of peptides and said he used BPC-157 for a muscle injury.
[verified] The advisory committee was reconstituted with roughly eight new members, several with ties to the peptide industry, ahead of the July meeting.
[verified] The FDA has no human clinical studies for TB-500 and KPV, and lacks adequate human data for the other peptides under review.
[verified] The FDA in 2023 (under Biden) restricted nearly 20 peptides from compounding, citing safety risks such as cancer and liver/kidney/heart problems.
The narrative clash
Whether a regulated compounding pathway makes peptides safer or more dangerous
Left: As people 'are diverted from those drugs toward this stuff, there will be more unnecessary pain and suffering'
Right: allowing peptides to be compounded by state-licensed pharmacies would provide greater oversight through prescription requirements, quality standards, inspections and adverse-event reporting
Whether the FDA process was legitimate or politically rigged
Left: actual neutral government experts were sidelined in favor of private industry people looking to make a buck
Right: All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members
Whether FDA's slow process harms US competitiveness
Left: allowing peptides on the market without clinical testing poses a 'profound threat' to FDA's decades-old system for vetting drugs
Right: Slow and prohibitive requirements for cutting edge therapies at the FDA means investment is increasingly flowing to China
Evidence standard — is the underlying data adequate to act on?
Left: There is not enough human data on these peptides; the agency's own scientists said no to all seven.
Right: The one-trial-at-a-time evidence standard is itself the problem and should be replaced with iterative, real-world learning.
Process — was going around FDA rulemaking an abuse or a necessary workaround?
Left: HHS skipped the lawful rulemaking process and issued a unilateral enforcement-discretion memo instead.
Right: FDA's slow, prohibitive process is the reason capital and cutting-edge therapy development are leaving the country, so moving around it is warranted.
100 sources analyzed
The New Republic NPR 90.3 KAZU Investor's Business Daily National Review Vox U.S. News & World Report Happi | Household And Personal Products Industry Reason City Journal The New Republic NPR KELO-AM Investor's Business Daily The New York Sun The Boston Globe WIRED foreignpolicyjournal.com The Center Square The Federalist The Boston Globe NBC News inkl Richmond Times-Dispatch The Federalist Salon The Mighty 790 KFGO Fortune Investor's Business Daily Fox News Daily Kos CNN Yahoo Finance Singapore Investor's Business Daily City Journal Common Dreams CBC Stocktwits Richmond Times-Dispatch National Review Vox PBS NewsHour STAT The Dispatch Fox News Mother Jones USA Today Nutritional Outlook Seeking Alpha The Federalist MSNBC Scientific American MedShadow Foundation The Dispatch The New York Sun The New Republic PBS NewsHour Endpoints News Richmond Times-Dispatch National Review Salon NPR CBS News Investor's Business Daily The New York Sun Common Dreams NBC News BBC Reason City Journal Mother Jones The Washington Post orrick.com The Dispatch The Federalist MSNBC NBC News Hims & Hers Newsroom Richmond Times-Dispatch City Journal The New Republic The Guardian Forbes The Center Square The New York Sun Common Dreams NBC News Men's Health The Center Square National Review Vox NPR The Hill The Dispatch The Boston Globe USA Today Bloomberg Law News Reason Mother Jones NBC News